Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis
Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis
复制标题
血清白细胞介素 6 水平的变化可作为托珠单抗治疗类风湿性关节炎疗效的预测指标
DOI：
10.1080/14397595.2017.1370766
复制
发表时间：
2018
影响因子：
2.2
通讯作者：
Kawano Mitsuhiro
中科院分区：
文献类型：
--
作者：
Aizu Motohiko;Mizushima Ichiro;Nakazaki Satoshi;Nakashima Akikatsu;Kato Takashi;Murayama Takashi;Kato Shinichi;Katsuki Yasuo;Ogane Kunihiro;Fujii Hiroshi;Yamada Kazunori;Nomura Hideki;Yachie Akihiro;Yamagishi Masakazu;Kawano Mitsuhiro
目的：我们旨在评估托珠单抗（TCZ）治疗的临床过程中血清IL-6的变化与类风湿性关节炎（RA）疾病活动或不良事件发生之间的关系。方法：每4周收集一次一般实验室数据，包括血清IL-6水平和体格检查结果，此外，在任何不良事件发生的时间。结果：20例血清IL-6 ≥ 30 pg/ml的患者在12周时达到临床疾病活动指数（CDAI）缓解的比例显著低于24例血清IL-6 <30 pg/ml的患者。24周时血清IL-6 ≥ 30 pg/ml者17例，CDAI缓解率明显低于血清IL-6 < 30 pg/ml者27例。17例患者52周时疾病活动度评分（DAS）、28-ESR和CDAI均显著高于血清IL-6 < 30 pg/ml者。经年龄和性别调整后的Logistic回归分析显示，12周时的logIL-6是52周时DAS 28-ESR缓解的预测因素。结论：TCZ开始后12 ~ 24周的血清IL-6水平更好地反映了TCZ在52周时的疗效。
Objectives:We aimed to evaluate the association between the change in serum IL-6 during the clinical course of tocilizumab (TCZ) therapy and rheumatoid arthritis (RA) disease activity or occurrence of adverse events.Methods:General laboratory data including serum IL-6 levels and physical findings were obtained every 4 weeks, and, in addition, at the time when any adverse events occurred.Results:The proportion achieving Clinical Disease Activity Index (CDAI) remission at 52 weeks was significantly lower in 20 patients with serum IL-6 ≥ 30 pg/ml at 12 weeks than 24 patients with serum IL-6 < 30 pg/ml. In 17 patients with serum IL-6 ≥ 30 pg/ml at 24 weeks, the proportion achieving CDAI remission was also significantly lower than 27 patients with serum IL-6 < 30 pg/ml then. In these 17 patients, Disease Activity Score (DAS) 28-ESR and CDAI at 52 weeks were significantly higher than those with serum IL-6 < 30 pg/ml. Age- and sex-adjusted logistic regression analysis showed logIL-6 at 12 weeks to be a predictive factor for DAS28-ESR remission at 52 weeks.Conclusion:Serum IL-6 levels from 12 to 24 weeks after TCZ initiation better reflect the efficacy of TCZ at 52 weeks.